Home/TScan Therapeutics/Gavin MacBeath
GM

Gavin MacBeath

Chief Executive Officer

TScan Therapeutics

TScan Therapeutics Pipeline

DrugIndicationPhase
TSC-101Hematologic malignancies (Acute Myeloid Leukemia, Myelodysplastic Syndromes)Phase 1
TSC-102-A01Hematologic malignanciesPreclinical
TSC-102-A03Hematologic malignanciesPreclinical
Multiple Unnamed TCR-T CandidatesSolid TumorsPreclinical
In Vivo-Engineered T Cell ProgramsNot Specified (Likely Cancer)Preclinical
Autoimmune Disease ProgramsAutoimmune DisordersDiscovery